<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03477630</url>
  </required_header>
  <id_info>
    <org_study_id>PRP 3.5 - 01 versión 1.3</org_study_id>
    <nct_id>NCT03477630</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoarthrosis of the Knee With Platelet Rich Plasma, Comparative Study With Hyaluronic Acid</brief_title>
  <official_title>Open Treatment for Pain and Inflammation in Knee Osteoarthrosis With Platelet-rich Plasma, Comparative Study With Hyaluronic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karla Andrea Arias Varela</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Varela, Karla Andrea Arias, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is using Plasma Rich Platelets to improve the negative symptoms of adult patients
      with osteoarthrosis of the knee. Half of the patients receive Plasma Rich Platelets. The
      other half receives hyaluronic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet Rich Plasma and hyaluronic acid are treatments injected directly into diseased
      knees. Both products reduce negative symptoms such as pain and inflammation. But they use
      different mechanisms. Plasma is a biological product that acts mainly as an anti-inflammatory
      reducing pain and collaborating to re establish the chemical balance within the knee, which
      slows down the deterioration of the joint.

      Hyaluronic acid is a knee lubricant that decreases friction and therefore stress inside the
      knee.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open, cohort, prospective study with a comparison group, randomized and one year follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pain intensity measures and functional limitation of the knee</measure>
    <time_frame>Day 0, 3 months, 6 months, 12 months.</time_frame>
    <description>2 item of Scale EVA for pain intensity associated with the activities of daily life as well as sports activities if practiced. Each item scored 0-100 ( 0: no pain, 100: pain as bad as can be). 11 item for Scale Lequesne.The total score is within the range between 0-24 points. Based on it, a severity scale is established: extremely serious, very serious, severe, moderate and mild. Scale Womac consists of 24 items. Each one is divided into 5 possible answers: none, little, enough, a lot and the highest.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infiltration, injected 6 cc per session, 1 sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Infiltration PRP 8cc per session, 4 sessions, 1 session every 15 days.</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>Infiltration 6 cc of HA , only once.</description>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <other_name>HA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Osteoarthrosis grade II, III and IV of Kellgren and Lawrence

          2. Chronic painful knee of mechanical characteristics.

          3. Absence of local or systemic septic process.

          4. Hematological and biochemical alterations that contraindicate the treatment.

          5. Informed consent in writing from the patient.

          6. The patient is able to understand the nature of the study

        Exclusion Criteria:

          1. Allergic to the egg

          2. Alteration in blood tests for platelet count in whole blood (hemogram)

          3. Patients presenting positive serology for HIV 1 and 2, Hepatitis B [HBsAg,
             Anti-HBV-Ab], Hepatitis C [Anti-HCV-Ab] and Lúes ).

          4. Participant who presents normal paper in the peripheral blood outside the range of
             normality (150.00 to 450,000).

          5. Patients with positive serology for HIV 1, and 2, VDRL, Hepatitis B [HBsAg, Anti HBs]
             Hepatitis C (HCV).6. Simultaneous participation in another clinical trial or treatment
             with another product in the experimental phase in the 30 days prior to inclusion in
             the study.

        7. Neoplastic disease 8. Immunosuppressive states. 9. Other pathologies or circumstances
        that compromise participation in the study according to medical criteria.

        10. The participant who has received intra-articular injection in knee with steroid deposit
        in the last 3 months. .

        11. Participant with religious or cultural conflicts due to the use of Platelet Rich
        Plasma.

        12. Participant who presents before the procedure a platelet count in whole blood outside
        the range of normality (150.00 to 450,000).

        13. Participant with infectious diseases active in blood. 14. Patients with anticoagulant
        treatment (warfarin, heparin) in the last 6 months.

        15. Participant with a history of skin, muscle or bone cancer in the lower limbs.

        16. Participant with psychological, emotional, social problems or any other situation that
        may interfere with the requirements of the study.

        17. Participant hospitalized for medical or surgical reasons.18. Participants with an
        arthroscopy in the last 6 months.

        19. Participants with severe osteoarthritis of the knee (Varo or Valgo)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Palavicini</last_name>
    <role>Study Director</role>
    <affiliation>FIFA MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínica Bíblica</name>
      <address>
        <city>San José</city>
        <zip>1307-100</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <reference>
    <citation>Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis. Am J Sports Med. 2016 Mar;44(3):792-800. doi: 10.1177/0363546515580787. Epub 2015 Apr 29.</citation>
    <PMID>25925602</PMID>
  </reference>
  <reference>
    <citation>Carrillo-Mora P, González-Villalva A, Macías-Hernández SI, Villaseñor CP. [Platelets-rich plasma: a versatile tool for regenerative medicine?]. Cir Cir. 2013 Jan-Feb;81(1):74-82. Review. Spanish.</citation>
    <PMID>23461926</PMID>
  </reference>
  <reference>
    <citation>Shahid M, Kundra R. Platelet-rich plasma (PRP) for knee disorders. EFORT Open Rev. 2017 Mar 13;2(1):28-34. doi: 10.1302/2058-5241.2.160004. eCollection 2017 Jan. Review.</citation>
    <PMID>28607768</PMID>
  </reference>
  <results_reference>
    <citation>Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, Babaee M, Azma K. Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015 Jan 7;8:1-8. doi: 10.4137/CMAMD.S17894. eCollection 2015.</citation>
    <PMID>25624776</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Varela, Karla Andrea Arias, M.D.</investigator_affiliation>
    <investigator_full_name>Karla Andrea Arias Varela</investigator_full_name>
    <investigator_title>Clinical Research</investigator_title>
  </responsible_party>
  <keyword>gonarthrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

